APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Summary

To assess: efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR…

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Solid Tumors
• Advanced Cancer
• Renal Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• NSCLC
• Lung Cancer
• Brain Tumor
• Glioblastoma Multiforme
• EGFR Gene Mutation
• MET Amplification
• HGF
• Thyroid Cancer
• Pancreatic Cancer
• Colon Cancer
• MET Alteration
• MET Fusion
• Exon 14 Skipping

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Apollomics Inc.

Last updated on ClinicalTrials.gov

June 27, 2025

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites